Again, MVA-BN-HER2 immunotherapy significantly delayed tumor growth (S2A Fig) and increased PD-L1 expression on tumor cells (CD45-) compared to control-treated mice (S2B–S2D Fig). The gene discussed is PTPRC; the disease is neoplasm.